Close this search box.

FDA Draft Guidance on Additional Notifications Under Section 506J | FDA

The article provides an overview of the regulatory framework for additional notifications related to medical devices.

MDCG Guidance on Legacy Devices Under the MDR: Non-Conformity and Timelines

Table of content

The Food and Drug Administration (FDA or the Agency), the US regulating authority in the sphere of healthcare products, has published a guidance document dedicated to the 506J device list and additional notifications.

Once finalised, the document will supplement the guidance dedicated to notifying the FDA of a permanent discontinuance or interruption in the manufacturing of a device under Section 506J of the FD&C Act to provide additional clarifications and recommendations to be taken into consideration by medical device manufacturers and other parties involved to ensure compliance with the applicable regulatory requirements.

At the same time, it is important to mention that provisions of the guidance are non-binding in their legal nature, nor are they intended to introduce new rules or impose new obligations.

Moreover, the authority explicitly states that an alternative approach could be applied, provided such an approach complies with the underlying legislation and has been agreed with the authority in advance.

Regulatory Background

First of all, it is important to mention that the present draft guidance issued by the FDA provides updates to the existing “506J Guidance” in light of the PREVENT Pandemics Act, part of the Consolidated Appropriations Act 2023.

This act mandates significant changes to the current regulatory framework, emphasizing the need for a more robust and responsive system to manage medical device supply chains, particularly during public health emergencies.

FDA on assessing credibility of computational modelling2

506J Device List

A key feature of the updated guidance is the introduction of the “506J Device List,” created in response to Executive Order 14001, which focuses on building a Sustainable Public Health Supply Chain.

The list, developed collaboratively by the FDA, other agencies, and industry stakeholders, identifies critical devices that require mandatory notification to the FDA in case of manufacturing discontinuance or interruption.

This list is dynamic and subject to regular updates, reflecting the changing needs and challenges in the healthcare sector.

Additional Notifications Under Section 506J

The document also describes the amendments to Section 506J, allowing the FDA to receive voluntary notifications from manufacturers about any permanent discontinuance or manufacturing interruption of a device, beyond the scenarios of a public health emergency.
This section underscores the importance of these notifications in mitigating device shortages, ensuring continuous supply, and maintaining public health safety.

The guidance further outlines specific scenarios and types of devices that require a 506J notification.
This includes unplanned manufacturing or distribution issues, increased demand beyond the manufacturer’s capacity, supply chain disruptions, and concerns related to software-enabled devices.
The goal is to ensure that the FDA is promptly informed about potential shortages or disruptions, allowing for timely interventions.

According to the document, manufacturers should submit the relevant notifications within seven days of identifying a manufacturing interruption or decision to discontinue a device.

The document details the necessary information to be included in these notifications, such as the nature of the disruption, estimated duration, and potential impact on supply. It also guides how these notifications should be submitted to the FDA.

As explained by the authority, the FDA uses the information from these notifications to proactively manage and prevent device shortages.

The guidance explains the process employed by the authority for analyzing this data, coordinating with manufacturers and other stakeholders, and implementing strategies to mitigate supply chain issues.


In summary, the approach described in the present draft guidance reflects the FDA’s commitment to ensuring a reliable supply of critical medical devices, particularly in the context of public health emergencies.
It provides a comprehensive framework for industry and FDA staff, outlining procedural and regulatory updates to better respond to the dynamic and evolving healthcare landscape.

How Can RegDesk Help?

RegDesk is a holistic Regulatory Information Management System that provides medical device and pharma companies with regulatory intelligence for over 120 markets worldwide. It can help you prepare and publish global applications, manage standards, run change assessments, and obtain real-time alerts on regulatory changes through a centralized platform. Our clients also have access to our network of over 4000 compliance experts worldwide to obtain verification on critical questions. Global expansion has never been this simple.


Want to know more about our solutions? Speak to a RegDesk Expert today!